Northern Trust Corp Acquires 41,298 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Northern Trust Corp increased its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 8.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 526,607 shares of the company’s stock after purchasing an additional 41,298 shares during the quarter. Northern Trust Corp owned 0.87% of Health Catalyst worth $3,723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Aquatic Capital Management LLC bought a new position in shares of Health Catalyst during the fourth quarter valued at $63,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Health Catalyst during the fourth quarter valued at $806,000. Two Sigma Securities LLC lifted its holdings in shares of Health Catalyst by 19.5% during the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock valued at $124,000 after purchasing an additional 2,862 shares in the last quarter. Penn Capital Management Company LLC bought a new position in shares of Health Catalyst during the fourth quarter valued at $3,506,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Health Catalyst by 8.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company’s stock valued at $442,000 after purchasing an additional 4,798 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Health Catalyst Stock Performance

Shares of HCAT opened at $3.65 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a 50-day simple moving average of $4.09 and a two-hundred day simple moving average of $5.70. The stock has a market cap of $254.04 million, a price-to-earnings ratio of -2.70 and a beta of 1.56. Health Catalyst, Inc. has a 52 week low of $3.56 and a 52 week high of $9.24.

Wall Street Analysts Forecast Growth

HCAT has been the subject of a number of research reports. Stephens reduced their price objective on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Royal Bank of Canada reduced their price objective on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Thursday, February 27th. Stifel Nicolaus upped their price objective on Health Catalyst from $5.00 to $5.50 and gave the company a “hold” rating in a research report on Thursday, May 8th. Canaccord Genuity Group reduced their price objective on Health Catalyst from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Finally, Citigroup reduced their price objective on Health Catalyst from $7.00 to $6.50 and set a “buy” rating for the company in a research report on Friday, April 25th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.00.

Insiders Place Their Bets

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the sale, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This represents a 7.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the sale, the chief operating officer now owns 216,250 shares of the company’s stock, valued at approximately $977,450. The trade was a 7.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 41,147 shares of company stock worth $182,284 over the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.